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BACKGROUND AND PURPOSE
Aristolochic acid (AristA) is found in plants used in traditional medicines to treat pain. We investigated the action of AristA on TREK
and TRESK, potassium (K2P) channels, which are potential therapeutic targets in pain. Balkan endemic nephropathy (BEN) is a
renal disease associated with AristA consumption. A mutation of TASK-2 (K2P5.1) channels (T108P) is seen in some patients sus-
ceptible to BEN, so we investigated how both this mutation and AristA affected TASK-2 channels.
EXPERIMENTAL APPROACH
Currents through wild-type and mutated human K2P channels expressed in tsA201 cells were measured using whole-cell patch-
clamp recordings in the presence and absence of AristA.
KEY RESULTS
TREK-1- and TREK-2-mediated currents were enhanced by AristA (100 μM), whereas TRESK was inhibited. Inhibition of TRESK did
not depend on the phosphorylation of key intracellular serines but was completely blocked by mutation of bulky residues in the
inner pore (F145A_F352A). The TASK-2_T108P mutation markedly reduced both current density and ion selectivity. A related
mutation (T108C) had similar but less marked effects. External alkalization and application of ﬂufenamic acid enhanced TASK-2
and TASK-2_T108C current but did not affect TASK-2_T108P current. AristA (300 μM) produced a modest enhancement of TASK-
2 current.
CONCLUSIONS AND IMPLICATIONS
Enhancement of TREK-1 and TREK-2 and inhibition of TRESK by AristA may contribute to therapeutically useful effects of this
compound in pain. Whilst AristA is unlikely to interact directly with TASK-2 channels in BEN, loss of functional TASK-2 channels
may indirectly increase susceptibility to AristA toxicity.
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Introduction
Aristolochic acid (AristA) is found in plants of the
Aristolochiaceae family, which have been used widely in tradi-
tional medicine for thousands of years. These plants are men-
tioned in early ﬁrst-century Roman texts as components of
frequently ingested medicines to treat a variety of conditions
including asthma, hiccups, spasms, pains and expulsion of
afterbirth, and they were described as components of certain
Chinese herbal medicines in the ﬁfth century AD (Scarbor-
ough, 2011). Although these herbal remedies were used for a
variety of conditions, a recurring theme was their use in
many cultures for the treatment of pain. For example,
Aristolochia clematitis (birthwort) has been used globally in
childbirth, chronic pain and arthritis (Debelle et al., 2008),
and Asarum caudatum (wild ginger) has been used in Chinese
and Native American herbal remedies for migraine, intestinal
pain and knee pain (Smith, 1929). The use of extracts of this
family of plants in the treatment of pain was particularly
widespread in Chinese herbal medicine. Aristolochia debilis
has been used for headache, abdominal pain and epigastric
pain, Aristolochia manshuriensis, as part of complex
prescriptions, as an anti-inﬂammatory treatment and
Aristolochia fangchi, also in complex prescriptions, as an
analgesic (IARC, 2002, 2012).
AristA has, however, been associated with nephropathy
leading to end-stage renal disease and also with urological
malignancies. This ﬁrst came to light when cases of nephritis
and kidney failure were seen in a group of women in Belgium
who had all taken a particular weight-loss supplement,
which, inadvertently, contained AristA (Vanherweghem
et al., 1993; Debelle et al., 2008). A recent pair of studies iden-
tiﬁed an AristA mutational signature in upper urinary tract
cancer patients from Taiwan (Hoang et al., 2013; Poon et al.,
2013) and showed that this carcinogenic effect of AristA is
amongst the most potent yet described. In animal studies, ei-
ther brief exposure to high concentrations (e.g. 50 mg·kg1
for 3 days) or extended exposure to low concentrations (e.g.
0.1 mg·kg1 for 12 months) causes a variety of malignant
tumours (IARC, 2012). As a result, AristA is now banned as a
component of herbal medicines inmany countries, including
the UK and USA (Debelle et al., 2008). Despite this, its use is
still widespread (Debelle et al., 2008). For example, fruits from
a variety of plants of the Aristolochiaceae family are freely
available in Iran and used to treat headache and back pain
(Ardalan et al., 2015).
Balkan endemic nephropathy (BEN) is a renal disease re-
stricted to rural areas of the Balkans and characterized by in-
sidious onset, chronic renal failure and strong association
with urothelial carcinoma of the upper urinary tract
(Grollman et al., 2007). It is widely believed that BEN is
caused by low-level AristA exposure, probably from contami-
nation of wheat ﬂour seeds by A. clematitis (Grollman et al.,
2007; De Broe, 2012; Bui-Klimke andWu, 2014). Because, like
the diseases associated with AristA-containing herbal medi-
cines, BEN is linked to AristA, this has prompted the use of
the term aristolochic acid nephropathy to describe all related
renal diseases associated with consumption of this com-
pound (e.g. De Broe, 2012). It is of interest that a number of
patients predisposed to BEN have been shown to carry a mu-
tation of the physiological important renal (Sepúlveda et al.,
2015) two-pore-domain potassium (K2P) channel, TASK-2
(K2P5.1) (Toncheva et al., 2014).
Despite the profound toxicity issues associated with
AristA, we were intrigued by the widespread use of this com-
pound in traditional medicine in the treatment of pain. A role
for K2P channels as therapeutic targets for the treatment of
pain has been proposed (e.g. Alloui et al., 2006; Mathie,
2010; Devilliers et al., 2013; Mathie and Veale, 2015), in par-
ticular the TREK (K2P2.1, K2P4.1, K2P10.1) and TRESK
(K2P18.1) families of K2P channels (as reviewed by Mathie
and Veale, 2015). The ﬁrst aim of this study, therefore, was
to investigate the action of AristA on these K2P channels to
determine whether this may contribute to its apparent thera-
peutic usefulness in the treatment of pain. The second aim of
this study was to describe how the mutation of TASK-2 chan-
nels seen in patients susceptible to BEN inﬂuenced the func-
tional properties of TASK-2 channels and to determine
whether AristA altered the activity of this K2P channel and
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Randomization
When comparisons are made between different recording
conditions or different, mutated, forms of a channel, record-
ings were alternated between one condition and the other
on a given experimental day.
Blinding
No blinding was undertaken in this study. It is not a usual pro-
cedure for this form of study and cannot be applied
retrospectively.
Normalization
No normalization of primary data was performed.
Statistical comparison
Group mean values and statistical analysis use independent
values. When comparing groups, a level of probability
(P < 0.05) was deemed to constitute the threshold for statisti-
cal signiﬁcance.
Cell culture
tsA201 cells (ECACC; Sigma-Aldrich, Gillingham, Dorset,
UK), modiﬁed human embryonic kidney 293 cells, were
grown in a monolayer tissue culture ﬂask maintained in a
growth medium, which was composed of 88% minimum es-
sential media with Earle’s salts and 2 mM L-glutamine, 10%
of heat-inactivated fetal bovine serum, 1% penicillin (10 000-
U·mL1) and streptomycin (10 mg·mL1) and 1% non-
essential amino acids. The cells were placed in an incubator
at 37°C with a humidiﬁed atmosphere of 95% oxygen and
5% carbon dioxide. After 2 or 3 days, when the cells were 70
to 90% conﬂuent, they were split and resuspended in a four-
well plate containing 13-mm-diameter cover slips (poly-D-ly-
sine coated) in 0.5 mL of media, ready to be transfected the
next day.
Transfection
For the electrophysiological experiments, the pcDNA3.1 vec-
tor was cloned with the gene of interest [hTREK-1 (or K2P2.1,
as designated by Alexander et al., 2015), hTREK-2 (K2P10.1),
hTRAAK (K2P4.1), hTRESK (K2P18.1), hTASK-2 (K2P5.1) and
hTASK-3 (K2P9.1) wild type (WT) and mutated]. The hTHIK-
1 (K2P13.1) gene was in the vector pcDNA3.1_NEO_N8. These
vectors and a similar vector containing GFP were incorpo-
rated into the tsA201 cells (0.5 μg per well) using the calcium
phosphatemethod. The cells were incubated for 6–12 h at 37°
C in 95% oxygen and 5% carbon dioxide. Cells were then
washed using a PBS solution, and new media added to each
well. The cells were used for experiments after 24 h.
Mutations
Point mutations were introduced by site-directed mutagene-
sis into the K2P channel clones using the Quikchange kit
(Stratagene, Amsterdam, the Netherlands). A pair of short
(25–35 bases) complementary oligonucleotide primers, incor-
porating the intended mutation, were synthesized (Euroﬁns
MWGOperon, Ebersberg, Germany). Mutant DNA constructs
were sequenced (Euroﬁns MWG Operon) to conﬁrm the in-
troduction of the correct mutated bases.
Whole-cell patch-clamp electrophysiology
Currents were recorded using the whole-cell patch clamp in a
voltage clamp conﬁguration in tsA201 cells transiently
transfected with the channel of interest. The cover slip with
the cells was placed in a recording chamber ﬁlled with an ex-
ternal medium composed of 145 mM NaCl, 2.5 mM KCl,
3 mM MgCl2, 1 mM CaCl2 and 10 mM HEPES (pH to 7.4,
using NaOH). In experiments where external [K] was varied,
NaCl was replaced with KCl to give the appropriate concen-
tration of K. The internal medium used in the glass pipette
comprised 150 mM KCl, 3 mM MgCl2, 5 mM (or 0.1 mM)
EGTA and 10 mMHEPES (pH to 7.4, using KOH). Modulatory
compounds were applied by bath perfusion at a rate of
4–5 mL·min1. Complete exchange of bath solution usually
occurred within 100–120 s; as such, any effect of these com-
pounds on current amplitude was only measured once the re-
sponse had reached steady state.
All the data presented have been collected at room tem-
perature (19–22°C). The transfected cells were detected using
a ﬂuorescent microscope with UV light. Cells were voltage
clamped using an Axopatch 1D or Axopatch 200B ampliﬁer
(Molecular Devices, Sunnyvale, CA, USA) and low-pass ﬁl-
tered at 5 kHz before sampling (2–10 kHz) and online capture.
In order to study the potassium leak current, a ‘step-ramp’
voltage protocol was used. For the step component of the pro-
tocol, cells were hyperpolarized from a holding voltage of
60 to 80 mV for 100 ms then stepped to 40 mV for
500 ms. For the ramp, cells were then stepped to 120 mV
for 100 ms, followed by a 500 ms voltage ramp to +20 mV
and a step back to 80 mV for another 100 ms, before being
returned to the holding voltage of 60 mV. This protocol
was composed of sweeps that lasted 1.5 s (including sampling
at the holding voltage) and was repeated once every 5 s (see
also Veale et al., 2014b).
Data analysis
For analysis of outward current, we measured the current differ-
ence between the 80 and 40 mV steps. The current–voltage
graphs were obtained from the ramp change in voltage between
120 and +20 mV. The currents obtained with the imposed
voltage protocol were recorded and analysed using PCLAMP
10.2 software andMicrosoft Excel. For each cell, the current am-
plitude (pA) was normalized to the cell capacitance (pF).
Data are expressed as mean ± SEM, and n represents the
number of cells used for the experiment. The statistical analyses
used either Student’s t-test (both paired and unpaired) or a one-
way ANOVAwith post hocDunnett’smultiple comparisons test,
using GRAPHPAD PRISM 6.02 (GraphPad Software, Inc., La Jolla,
CA, USA). For the t-test, the differences between means were
considered as signiﬁcant for P < 0.05. For the Dunnett’s test,
data were considered signiﬁcantly different at the <0.05 level
(conﬁdence interval > 95% for the difference between the two
compared means). Concentration–response data were ﬁtted
using the Hill equation. The data and statistical analysis comply
with the recommendations on experimental design and analy-
sis in pharmacology (Curtis et al., 2015).
Chemicals
All ﬁne chemicals were purchased from Sigma-Aldrich.
Flufenamic acid (FFA) stock (10 mM) was made up in ethanol
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and diluted fresh in external solution before use (pH adjusted
to 7.4). Aristolochic acid I (AristA) stock (50 mM) was made
up in water and diluted in fresh external before use (pH ad-
justed to 7.4). Extracts of Aristolochia species comprise,
primarily, of a mixture of aristolochic acid I and its
demethoxylated derivative, aristolochic acid II. In this study,
we used puriﬁed aristolochic acid 1 (Figure 1), and the term
aristolochic acid (AristA) is used to denote this.
Results
AristA enhances TREK-1 and TREK-2 channel
currents
Application of AristA (aristolochic acid I, see Section on
Methods; 100 μM) resulted in an enhancement of current
through TREK-1 and TREK-2 channels of 26 ± 6%
(mean ± SEM, n = 6) and 44 ± 11% (n = 6), respectively,
when current is measured as the difference current between
that seen at 40 mV and that at 80 mV (see Section on
Methods). Enhancement of both currents was rapid and
easily reversible (Figure 2A–D). There was some voltage-
dependence to the enhancement for both currents. This is
illustrated for exemplar cells in the range 60 to +20 mV for
either current (Figure 2 insets). Enhancement of TREK-1 was
42 ± 9% (n = 6) at 60 mV, which was signiﬁcantly larger
than the 17 ± 6% (n = 6) enhancement at +20 mV in the
same cells. For TREK-2, enhancement was 50 ± 14% (n = 5)
at 60 mV compared with 17 ± 3% (n = 5) at +20 mV in the
Figure 1
Structure of AristA. Adapted from IARC (2012).
Figure 2
Aristolochic acid (AristA) enhances TREK-1 and TREK-2 currents, with apparent voltage-dependence. (A) Time course plot showing an enhance-
ment of human TREK-1 current transiently expressed in tsA201 cells by AristA (100 μM). Each point is a 5 ms average of the difference current
between that at40mV and that at80mV (seeMethods for detailed description of voltage ramp protocol). (B) TREK-1 currents evoked by ramp
changes in voltage from 120 to +20 mV in control conditions and in the presence of 100 μM AristA. Inset shows percentage enhancement of
TREK-1 current by 100 μM AristA plotted as a function of voltage. (C) Time course plot showing an enhancement of human TREK-2 current by
AristA (100 μM). Inset shows percentage enhancement of TREK-2 current by 100 μM AristA plotted as a function of voltage. (D) TREK-2 currents
evoked by ramp changes in voltage in control conditions and in the presence of 100 μM AristA.
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same cells. Thus, enhancement was greater near the reversal
potential of the currents and therefore near the resting
membrane potential of cells in which they are expressed. In
some recordings for both TREK-1 and TREK-2 (Figure 2A and
C), there does appear to be a biphasic response to AristA
(100 μM) with an ‘over-recovery’ on washout leading to a
sustained reduced current amplitude compared with that
measured before application of the drug. However, a lower
concentration of the compound (1 μM) had no detectable
effect on either TREK-1 or TREK-2.
By contrast, AristA (100 μM) had little effect on currents
mediated through TRAAK channels (Figure 3A and B) with
an enhancement of 8 ± 5% (n = 5), or on the short form of
TREK-1 channels (TREK-1_ΔN, Figure 3C and D), formed by
alternative translation initiation (Thomas et al., 2008; Veale
et al., 2010; 2014a), with an enhancement of 4 ± 5%
(n = 5). This was despite the fact that both of these channels
could be substantially enhanced by ﬂufenamic acid (Veale
et al., 2014a) in recordings from the same cells (Figure 3A
and C).
TREK channel activity is subject to convergent, poly-
modal regulation by a variety of factors including tempera-
ture, pressure and the phosphorylation state of the channel,
and this may inﬂuence the response of the channels to other
regulatory compounds (Bagriantsev et al., 2012). Recent
experiments by Bagriantsev et al. (2012) showed that a triple
glycine (3G) mutant, which decouples the intracellular C
terminal tail of the channels from the pore-forming core, ren-
dered the channels insensitive to polymodal regulation by
the aforementioned factors. Bagriantsev et al. (2013) found
that the TREK channel activator, ML67-33, still activated
these mutated channels. We have made the corresponding
3G mutant of TREK-2 (TREK-2_I318G_G319_D320G). These
channels were still enhanced by 100 μM AristA (26 ± 5%,
n = 5), and this enhancement was not signiﬁcantly different
to that seen for WT TREK-2 channels (44 ± 11%, n = 6). This
suggests that enhancement of TREK-2 channels by AristA oc-
curs independently from polymodal regulation through the
intracellular C terminal tail of the channel.
AristA inhibits TRESK channel currents
In contrast to the enhancement seen at high concentrations
for TREK-1 and TREK-2 channels, we observed that AristA
was an inhibitor of TRESK channels (Figure 4A and B).
Inhibition had a fast onset but was only slowly reversible, par-
ticularly at higher concentrations such as 100 μM (Figure 4A),
with a calculated 50% effective concentration of 13 ± 2 μM for
AristA on TRESK and a Hill slope of 0.56 ± 0.08 (Figure 4C). As
for enhancement of TREK channels, the effect of AristA was
voltage-dependent. This is illustrated for an exemplar cell in
Figure 4D. Inhibition of TRESK by 100 μM AristA was
Figure 3
Aristolochic acid (AristA) has no effect on the closely related two-pore-domain potassium channel, TRAAK and the N-terminally truncated TREK-1
isoform (TREK-1_ΔN). (A) Time course plot showing lack of effect of AristA (100 μM) on human TRAAK isoform 2 (the sequence of this isoform
differs from the canonical sequence by the addition of 26 amino acids, preceding the start codon of isoform 1). (B) TRAAK currents evoked by
ramp changes in voltage in control conditions and in the presence of 100 μM AristA. (C) Time course plot showing lack of effect of AristA
(100 μM) on the alternative translational initiation isoform of TREK-1 (TREK-1_ΔN), where the ﬁrst 41 amino acids of wild-type TREK-1 are missing.
(D) TREK-1_ΔN currents evoked by ramp changes in voltage in control conditions and in the presence of 100 μM AristA.
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96 ± 6% (n = 6) at 60 mV, which was signiﬁcantly larger
than the 56 ± 5% (n = 6) inhibition seen at +20 mV in the
same cells. At +20 mV, AristA had a calculated 50% effective
concentration of 86 ± 3 μM with a Hill slope of 0.34 ± 0.11.
Thus, as with enhancement of TREK-1 and TREK-2 channels,
inhibition of TRESK was greater around the reversal potential
of the currents and therefore around the resting membrane
potential of cells in which they are expressed.
AristA and TRESK channel mutants
TRESK channels expressed in oocytes have been shown to be
directly regulated by increases in intracellular calcium
through activation of the calcium/calmodulin-dependent
phosphatase calcineurin (e.g. Czirják and Enyedi, 2010).
We, therefore, carried out a number of experiments to inves-
tigate the potential role of AristA in calcium-dependent pro-
cesses. In the ﬁrst set of experiments, we altered the internal
calcium buffer in the recording solution between 0.1 mM
(‘low’ EGTA) and 5mM (‘high’ EGTA). This had no signiﬁcant
effect on inhibition by AristA (100 μM) with 73 ± 4% (n = 6)
inhibition in low EGTA and 79 ± 2% (n = 6) inhibition in high
EGTA. Thus, inhibition was unaffected by the degree of intra-
cellular calcium buffering.
For mouse TRESK channels, Czirják and Enyedi (2010)
have shown that mutation of key serine residues, located in
the large intracellular loop between transmembrane domains
M2 andM3, can abolish the effects of phosphatase action.We
thus created two mutant human TRESK channels,
S252E_S264E to mimic the phosphorylated form of the chan-
nel and S252A_S264A to mimic the dephosphorylated form
of the channel.
For S252A_S264A channels, current density was signiﬁ-
cantly larger than WT channels (48 ± 3 pA/pF, n = 31, for
the mutated channels compared with 27 ± 2 pA/pF, n = 28,
for WT TRESK channels); however, AristA (100 μM) still
inhibited channel current by 80 ± 2% (n = 6, Figure 5A and
B). For S252E_S264E channels, current density was not signif-
icantly different toWT channels (33 ± 3 pA/pF, n = 39). AristA
(100 μM) was, again, able to inhibit current through these
channels by 73 ± 5% (n = 5) (Figure 5C and D). The inhibition
of either phosphorylation mutant by AristA was not signiﬁ-
cantly different to that of WT TRESK.
Recently, mutation of two amino acids in the M2 and M4
inner pore regions of mouse TRESK channels (equivalent to
F145A_F352A in human TRESK) has been shown to occlude
the action of a number of different blocking drugs of the
channel, and it was proposed that this position forms a bind-
ing site for blockers targeting TRESK channels (Kim et al.,
2013; Bruner et al., 2014). We investigated the effect of this
double mutation on the action of AristA on TRESK channels.
We found that AristA (100 μM) no longer inhibited current
through these mutated channels (0 ± 5%, n = 7, Figure 5E
and F).
Figure 4
Aristolochic acid (AristA) inhibits TRESK-mediated currents with apparent voltage-dependence. (A) Time course plot showing an inhibition of hu-
man TRESK current by AristA (100 μM). (B) TRESK currents evoked by ramp changes in voltage in control conditions and in the presence of 100 μM
AristA. (C) Concentration–response curve for AristA inhibition of TRESK current. (D) Percentage inhibition of TRESK current by 100 μMAristA plot-
ted as a function of voltage.
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TASK-2, AristA and BEN
AristA has been implicated in BEN (see Introduction). A re-
cent paper has suggested that a number of patients suffering
from BEN have a mutation in the coding region of the K2P
channel, TASK-2, namely T108P , suggesting an important
role of TASK-2 channels in BEN predisposition (Toncheva
et al., 2014). Given the potential importance of both AristA
and TASK-2 channels in BEN, we were interested, therefore,
to determine whether AristA interacted with either (or both)
of the WT or the T108P mutated form of TASK-2. Initially,
however, we characterized the properties of these T108P mu-
tated TASK-2 channels.
Figure 6A–C shows currents through WT TASK-2 chan-
nels, TASK-2_T108P channels and a more conservatively mu-
tated TASK-2 channel at the same residue, TASK-2_T108C, in
a variety of external K+ concentrations. In contrast toWT and
Figure 5
Aristolochic acid (AristA) inhibits serine phosphorylation mutants of TRESK, but its effect is signiﬁcantly attenuated by the phenylalanine mutants
in the inner pore. (A) Time course plot showing an inhibition of the phosphorylation mutant TRESK_S252A_S264A by AristA (100 μM). (B)
TRESK_S252A_S264A currents evoked by ramp changes in voltage in control conditions and in the presence of 100 μM AristA. (C) Time course
plot showing an inhibition of the phosphorylation mutant TRESK_S252E_S264E by AristA (100 μM). (D) TRESK_S252E_S264E currents evoked
by ramp changes in voltage in control conditions and in the presence of 100 μM AristA. (E) Time course plot showing lack of effect on mutant
TRESK_F145A_F352A by AristA (100 μM). (F) TRESK_F145A_F352A currents evoked by ramp changes in voltage in control conditions and in
the presence of 100 μM AristA.
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TASK-2_T108C channels, there is very little current through
TASK-2_T108P mutated channels regardless of the external
K+ concentration. For example, in 2.5 mM external K+, cur-
rent density for WT TASK-2 was 52 ± 4 pA/pF (n = 27); for
TASK-2_T108C, it was 9 ± 1 pA/pF (n = 15), and for TASK-
2_T108P , it was just 2 ± 1 pA/pF (n = 26). Both mutations
had signiﬁcantly smaller current density than WT TASK-2.
Furthermore, unlike WT TASK-2 channels, the reversal
potential of TASK-2_T108P channels measured in different
external [K+] are not consistent with the presence of a K+-se-
lective current (Figure 6D). For example, in 2.5 mM external
K+, reversal of current for WT TASK-2 was 86 ± 1 mV
(n = 27), but for TASK-2_T108P , this was 43 ± 3 mV
(n = 26). It is of interest that the TASK-2_T108C channel also
showed a reduced K+ selectivity with a reversal potential in
2.5 mM external K+ of 70 ± 3 mV (n = 15).
Activators of TASK-2 channels
We next considered whether activators of TASK-2 channels
might induce current through T108P mutated channels, as
has been seen previously for other non-functional or
reduced-function, mutated K2P channels (Ma et al., 2013;
Veale et al., 2014a,b). Changes in external pH are known to
regulate TASK-2 channels (Reyes et al., 1998). Figure 7A and
B illustrates that very similar regulation by external pH for
TASK-2_T108C channels to that known for WT TASK-2 chan-
nels occurs, with clear enhancement of current at pH 8.4 and
inhibition at pH 6.4 compared with pH 7.4. We found a
120 ± 17% (n = 9) enhancement at pH 8.4 for WT TASK-2
and a 143 ± 22% (n = 9) enhancement for TASK-2_T108C
channels. The reversal potential at pH 8.4 (in 2.5 mM exter-
nal K+) was 91 ± 3 mV (n = 5) for WT TASK-2 and
76 ± 3 mV (n = 7) for TASK-2_T108C channels. However,
in contrast, pH 8.4 had no effect on TASK-2_T108P channels
(Figure 7C and D) with 10 ± 12% (n = 7) enhancement of cur-
rent and a reversal potential of 52 ± 5 mV (n = 7) at pH 8.4.
FFA (100 μM) is a known enhancer of several K2P chan-
nels (Veale et al., 2014a,b; see also Figure 2). We showed that
this compound is also able to enhance current through both
WT TASK-2 channels (Figure 8A and B) and TASK-2_T108C
channels (Figure 8C and D). We found an 80 ± 31% (n = 7)
enhancement for WT TASK-2 by FFA and a 97 ± 25% (n = 6)
enhancement for TASK-2_T108C channels. The reversal
potential in FFA (in 2.5 mM external K) was 90 ± 3 mV
(n = 7) for WT TASK-2 and 72 ± 7 mV (n = 6) for TASK-
2_T108C channels. However, FFA (100 μM) produced no en-
hancement of TASK-2_T108P channels (Figure 8E and F) with
15 ± 14% (n = 9) inhibition of current and a reversal potential
of 44 ± 4 mV (n = 9) in FFA.
AristA and TASK-2 channels
At 100 μM, AristA has no effect on WT TASK-2, TASK-2_T108C
or TASK-2_T108P channels. However, at a concentration of
300 μM, AristA was able to induce a very modest enhancement
of WT TASK-2 channels (Figure 9A and B, 21 ± 13%, n = 5).
At this high concentration, AristA also produced a very small
Figure 6
Characteristics of currents through WT TASK-2, TASK-2_T108C and TASK-2_T108P channels in varying concentrations of extracellular potassium
(K
+
). (A) Currents recorded through wild-type TASK-2 channels in 2.5 mM K
+
, 25 mM K
+
and 147.5 mM K
+
. Currents evoked by ramp changes in
voltage from 120 to +20 mV, as detailed in Methods. (B) Currents recorded through TASK-2_T108C channels in 2.5 mM K
+





. (C) Currents recorded through TASK-2_T108P channels in 2.5 mM K
+
, 25 mM K
+
and 147.5 mM K
+
. (D) Plot of reversal potential
versus external K
+
concentration for WT TASK-2, TASK-2_T108C and TASK-2_T108P.
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enhancement of TASK-2_T108P channels (Figure 9C and D,
12 ± 6%, n = 5) although current density of these channels
remained unaltered compared with the absence of AristA at
2 ± 1 pA/pF (n = 5). Furthermore, the reversal potential of these
currents through TASK-2_T108P in the presence of AristA in
2.5 mM external [K+] was 40 ± 4 mV (n = 5), still inconsistent
with the presence of a K+ selective current.
Discussion
In this study, we have shown that AristA has a range of ac-
tions on K2P channels. This is summarized for all K2P chan-
nels tested for a single concentration of AristA (100 μM) in
Figure 10, where the percentage change in current in the
presence of AristA compared with that in the absence of
the compound is measured. The TREK family members,
TREK-1 and TREK-2, are the only K2P channels to show
substantive enhancement by AristA, whereas TRESK chan-
nels, which are the most distant from TREK channels in
terms of sequence homology (e.g. Enyedi and Czirják,
2010; Feliciangeli et al., 2015), are the only channels that
are inhibited by AristA. There is no substantive effect of
AristA, at this concentration, on TRAAK, TASK-3, THIK-1
or TASK-2 channels.
Mechanism of action of AristA
AristA is a non-selective agent that has been suggested to reg-
ulate the activity of a number of different ion channels. For
example, TRPA1/ ﬂies have been shown to have a reduced
avoidance to AristA, and AristA induces action potential ﬁr-
ing in these ﬂies (Kim et al., 2010). However, this effect of
AristA is not linked to direct effect on TRPA1 channels (Kim
et al., 2010). AristA has also been demonstrated to inﬂuence
the activity of certain K+ channels (Lopes et al., 1998; Roch
et al., 2006), but again, these are supposed to be indirect ac-
tions. In these studies, AristA was proposed to work through
block of the enzyme phospholipase A2 (Soderquist et al.,
2014). Phospholipase A2 is a calcium-dependent enzyme that
generates arachidonic acid. It is unlikely that block of phos-
pholipase A2 underlies the substantive effects on TREK and
TRESK channels seen here, because arachidonic acid en-
hances TREK (and TRAAK) channels (Fink et al., 1996; Enyedi
and Czirják, 2010) and blocks TRESK channels (Sano et al.,
2003; Kang et al., 2004). Thus, AristA should produce the op-
posite effects to those observed here if it were working
through block of phospholipase A2, namely, an inhibition
of TREK (and TRAAK) channels and an enhancement of
TRESK channels. Furthermore, we have shown that inhibi-
tion of TRESK does not depend on the intracellular calcium
concentration determined by varying the concentration of
intracellular calcium buffer, EGTA.
Figure 7
Effect of changes in extracellular pH on mutant TASK-2 channels. (A) Representative time course for enhancement and inhibition of outward cur-
rent by extracellular alkalization and acidiﬁcation, respectively, through TASK-2_T108C channels. (B) TASK-2_T108C currents evoked by ramp
changes in voltage in control solution (pH 7.4), pH 8.4 and pH 6.4. (C) Representative time course for changes of outward current by extracellular
alkalization through TASK-2_T108P channels. (D) TASK-2_T108P currents evoked by ramp changes in voltage in control solution (pH 7.4) and in
alkaline solution (pH 8.4).
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Inhibition of TRESK channels by AristA also does not
work through calcium-mediated stimulation of phosphatase
activity, nor does it depend on the phosphorylation state of
the channel on key serine residues in the intracellular loop
between M2 and M3, known to be regulated by phosphatase
activity (Czirják et al., 2004; Czirják and Enyedi, 2006, 2010;
Enyedi and Czirják, 2015), because it still caused substantive
inhibition of both the permanently ‘phosphorylated’ form
of the channel (S252E_S264E) and the permanently ‘dephos-
phorylated’ form of the channel (S252A_S264A). This can be
contrasted with the block of TRESK channels by benzocaine,
which is dependent on the phosphorylation state of these ser-
ine residues on the channel (Czirják and Enyedi, 2006).
Mutation of two bulky amino acids in the M2 and M4
inner pore regions of mTRESK channels (equivalent to
F145A_F352A in hTRESK) has been shown to occlude the
Figure 8
Regulation of WT TASK-2, TASK-2_T108C and TASK-2_T108P mutant channels by ﬂufenamic acid (FFA). (A) Representative time course for en-
hancement of outward current by FFA (100 μM) for current through WT TASK-2 channels. (B) Current–voltage relationships for WT TASK-2 chan-
nels in the absence and presence of FFA (100 μM). (C) Representative time course for enhancement of outward current by FFA (100 μM) for
current through TASK-2_T108Cmutant channels. (D) Current–voltage relationships for TASK-2_T108Cmutant channels in the absence and pres-
ence of FFA (100 μM). (E) Representative time course demonstrating lack of effect on the outward current by FFA (100 μM) on current through
TASK-2_T108P mutant channels. (F) Current–voltage relationships for TASK-2_T108P mutant channels in the absence and presence of FFA
(100 μM).
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action of a number of different blocking drugs of the channel,
and it was proposed that this position forms a binding site for
blockers targeting TRESK channels (Kim et al., 2013; Bruner
et al., 2014). These mutations also occlude the action of
AristA and increase TRESK current density. Inhibition by
AristA is voltage-dependent, consistent with the idea
that these amino acids, in the inner pore, may contribute to
the binding site for AristA. However, we cannot exclude the
possibility that these amino acids are important in regulating
gating of the channel rather than forming a binding site,
per se.
Enhancement of TREK-1 and TREK-2 channels
in the treatment of pain
TREK-1/ mice have been found to be more sensitive than
WT mice to painful heat sensations (Alloui et al., 2006). Fur-
thermore, more recent work has shown that morphine, act-
ing through μ opioid receptors, enhances TREK-1 current
directly. In the same study, TREK-1/ animals showed sig-
niﬁcantly less morphine-induced analgesia than WT animals
(Devilliers et al., 2013). In both small- and medium-sized dor-
sal root ganglion neurons, single-channel and whole-cell
patch recordings suggested that TREK-2 channels were most
likely to underlie a substantial portion of background current
present in these cells (Kang and Kim, 2006; Marsh et al.,
2012). More recently, TREK-2 channels have been shown to
be selectively expressed in IB4 binding C nociceptors (Acosta
et al., 2014) and contribute to the resting membrane potential
of these neurons. As such, it was proposed that TREK-2 expres-
sion might act to limit pathological pain (Acosta et al., 2014).
Enhancement of both TREK-1 and TREK-2 channel activity
by AristA would contribute to a therapeutically useful effect
of this compound in pain and may help to explain the persis-
tent use of plant extracts containing this compound in herbal
remedies for pain (see Introduction; IARC, 2002, 2012).
Inhibition of TRESK channels and pain
The potential importance of TRESK channels in pain associ-
ated with migraine was highlighted by the observation that
familial migraine with aura is associated with a dominant-
negative mutation in TRESK channels (Lafrenière et al.,
2010; Enyedi and Czirják, 2015). This suggests that decreased
TRESK channel activity might exacerbate migraine pain and
that activators of TRESK channels might provide a useful
therapeutic approach in pain, particularly given their rather
restricted expression in certain central neurons, spinal cord
and nociceptive sensory neurons (Kang and Kim, 2006;
Dobler et al., 2007; Lafrenière et al., 2010; Marsh et al., 2012).
Hydroxy-α-sanshool, a primary active ingredient of
Szechuan peppers, has been shown to block TRESK channels,
and this action on TRESK channels has been proposed to un-
derlie the distinctive numbing effect induced by this natural,
Figure 9
Regulation of WT TASK-2 and TASK-2_T108P mutant channels by aristolochic acid (AristA). (A) Representative time course for enhancement of
outward current by AA (300 μM) for current through WT TASK-2 channels. (B) Current–voltage relationships for WT TASK-2 channels in the ab-
sence and presence of AristA (300 μM). (C) Representative time course for the outward current of TASK-2_T108P channels in the presence and
absence of AristA (300 μM). (D) Current–voltage relationships for TASK-2_T108P channels in the absence and presence of AristA (300 μM).
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widely used analgesic (Bautista et al., 2008). This is a rather
paradoxical observation given that TRESK channel activity
is inhibited rather than enhanced by hydroxy-α-sanshool.
However, it is possible that the tingling paraesthesia
(Lennertz et al., 2010) induced by hydroxy-α-sanshool even-
tually leads to desensitization of the excited neurons and a
numbing of the sensation of pain in a manner analogous to
that seen for the nociceptive agent, capsaicin, albeit through
a different molecular mechanism (Mathie, 2010; Mathie and
Veale, 2015). Because AristA is a potent inhibitor of TRESK
channels, it might be predicted to act in a similar manner to
hydroxy-α-sanshool to produce analgesia.
The voltage dependence of the effect of AristA on TREK-1,
TREK-2 and TRESK channels shows that the effect of the com-
pound is most prominent around the resting membrane po-
tential of cells. This suggests that, in sensory neurons,
AristA is most effective at membrane potentials that regulate
the excitability and ﬁring frequency of these neurons either
dampening (for TREK-1 and TREK-2) or increasing (for TRESK)
excitability. However, given that different K2P channels con-
tribute differently to the resting membrane potential in differ-
ent neuronal subpopulations, this is likely to be a complex,
non-linear mechanism.
TASK-2 channels and BEN
The mutation T108P in TASK-2 channels is found in a num-
ber of patients diagnosed with BEN. This suggests that this
mutation predisposes these patients to the disease because
the proportion of BEN patients with this mutation is much
larger than that seen in the general population (Toncheva
et al., 2014). We have found that this mutation markedly re-
duces TASK-2 channel current density and alters the ion
selectivity of the current, so that it is no longer potassium
selective. Because we do not have a functional, tagged form
of TASK-2_T108P at present, we cannot exclude the possibil-
ity that this channel gives a small current because it does
not express well at themembrane. Amore conservativemuta-
tion at the same site (T108C) also reduces current density but
not to nearly the same degree and slightly alters ion selectiv-
ity. This threonine residue is located at the top of the M2
transmembrane domain of TASK-2, close to the channel se-
lectivity ﬁlter, and it is present in 13 out of the 15mammalian
K2P channels (Mathie et al., 2010). In other K2P channels,
this threonine residue is known to inﬂuence channel gating
(Zilberberg et al., 2001; Mathie et al., 2010). External
alkalization (to pH 8.4) and application of FFA were shown
to enhance current through both WT TASK-2 channels and
TASK-2_T108C channels to around the same degree. These
two treatments, however, caused no enhancement of TASK-
2_T108P channels and did not inﬂuence the ion selectivity
of this mutated channel.
TASK-2 has an important role in renal function (Cid et al.,
2013). Indeed, it is highly expressed in renal tissue andwas orig-
inally isolated and cloned from human kidney (Reyes et al.,
1998). It is highly expressed in the basolateral membrane of
proximal tubule cells (Warth et al., 2004). TASK-2/mice have
been shown to have a reduced capacity for HCO3
 transport,
which leads to proximal renal tubular acidosis (Warth et al.,
2004; Sepúlveda et al., 2015). Poor or non-functioning TASK-2
channels in patients carrying the T108P mutation would be an-
ticipated to produce similar effects in these patients and com-
promise renal function. Furthermore, because TASK-2
channels form functional dimers, it is likely that the T108Pmu-
tation will act as a dominant negative in these patients.
TASK-2 channels expressed in the retrotrapezoid nucleus
regulate the ventilator response to CO2 (Bayliss et al., 2015),
but a parallel pathway mediated through the proton-
activated receptor GPR4 acts as a distinct central mediator
of respiratory chemosensitivity (Kumar et al., 2015). In this
way, independent molecular pH sensors provide redundancy
for this vital physiological function. It is possible, therefore,
that similar independent parallel processes may exist to com-
pensate for TASK-2 in the kidney, if required.
We have found that AristA has little effect on either WT
TASK-2 channels or on TASK-2_T108P channels except to in-
duce a very modest enhancement of current through these
channels at a high concentration (300 μM). This suggests that
AristA is unlikely to interact directly with TASK-2 channels in
contributing to its action in BEN. Rather, loss of functional
TASK-2 channels in BEN (such as in patients with the T108P
mutation) may indirectly increase susceptibility to AristA
toxicity (and thus to BEN) acting through independent mo-
lecular pathway(s).
Acknowledgements
Supported by the Biotechnology and Biological Sciences
Research Council (UK) [BB/J000930/1] and Pﬁzer.
Author contributions
A.M and E.L.V participated in research design, E.L.V
conducted experiments, E.L.V and A.M performed data
analysis, A.M and E.L.V wrote the manuscript.
Conﬂict of interest
The authors declare no conﬂicts of interest.
Figure 10
Effect of aristolochic acid (AristA) at 100 μM on representative hu-
man two-pore-domain potassium (K2P) channels. The effet on each
channel is shown at two different voltages (60 and +20 mV). Rep-
resentative time courses for THIK-1 and TASK-3 channels are given
in the Supporting Information.
BJP
E L Veale and A Mathie
12 British Journal of Pharmacology (2016) •• ••–••
Declaration of transparency and
scientiﬁc rigour
This Declaration acknowledges that this paper adheres to the
principles for transparent reporting and scientiﬁc rigour of pre-
clinical research recommended by funding agencies, publishers
and other organizations engaged with supporting research.
References
Alexander SPH, Catterall WA, Kelly E, Marrion N, Peters JA, Benson
HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16:
Voltage-gated ion channels. Br J Pharmacol 172: 5904–5941.
Acosta C, Djouhri L, Watkins R, Berry C, Bromage K, Lawson SN
(2014). TREK2 expressed selectively in IB4-binding C-ﬁber
nociceptors hyperpolarizes their membrane potentials and limits
spontaneous pain. J Neurosci 34: 1494–1509.
Alloui A, Zimmermann K, Mamet J, Duprat F, Noël J, Chemin J et al.
(2006). TREK1, a K+ channel involved in polymodal pain perception.
EMBO J 25: 2368–2376.
Ardalan MR, Khodaie L, Nasri H, Jouyban A (2015). Herbs and
hazards: risk of aristolochic acid nephropathy in Iran. Iran J Kidney
Dis 9: 14–17.
Bagriantsev SN, Ang KH, Gallardo-Godoy A, Clark KA, Arkin MR,
Renslo AR et al. (2013). A high-throughput functional screen
identiﬁes small molecule regulators of temperature- and mechano-
sensitive K2P channels. ACS Chem Biol 8: 1841–1851.
Bagriantsev SN, Clark KA, Minor DL Jr (2012). Metabolic and thermal
stimuli control K(2P)2.1 (TREK1) through modular sensory and
gating domains. EMBO J 31: 3297–3308.
Bautista DM, Sigal YM, Milstein AD, Garrison JL, Zorn JA, Tsuruda PR
et al. (2008). Pungent agents from Szechuan peppers excite sensory
neurons by inhibiting two-pore potassium channels. Nat Neurosci
11: 772–779.
Bayliss DA, Barhanin J, Gestreau C, Guyenet PG (2015). The role of
pH-sensitive TASK channels in central respiratory chemoreception.
Pﬂugers Arch 467: 917–929.
Bruner JK, Zou B, Zhang H, Zhang Y , Schmidt K, Li M (2014).
Identiﬁcation of novel small molecule modulators of K2P18.1 two-
pore potassium channel. Eur J Pharmacol 740: 603–610.
Bui-Klimke T, Wu F (2014). Evaluating weight of evidence in the
mystery of Balkan endemic nephropathy. Risk Anal 34: 1688–1705.
Cid LP , Roa-Rojas HA, Niemeyer MI, González W, Araki M, Araki K
et al. (2013). TASK-2: a K2P K(+) channel with complex regulation and
diverse physiological functions. Front Physiol 4: 198. doi: 10.3389/
fphys.2013.00198
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP , Giembycz
MA et al. (2015). Experimental design and analysis and their
reporting: new guidance for publication in BJP . Br J Pharmacol 172:
3461–3471.
Czirják G, Tóth ZE, Enyedi P (2004). The two-pore domain K+
channel, TRESK, is activated by the cytoplasmic calcium signal
through calcineurin. J Biol Chem 279: 18550–18558.
Czirják G, Enyedi P (2006). Targeting of calcineurin to an NFAT-like
docking site is required for the calcium-dependent activation of the
background K+ channel, TRESK. J Biol Chem 281: 14677–14682.
Czirják G, Enyedi P (2010). TRESK background K(+) channel is
inhibited by phosphorylation via two distinct pathways. J Biol Chem
285: 14549–14557.
Debelle FD, Vanherweghem JL, Nortier JL (2008). Aristolochic acid
nephropathy: a worldwide problem. Kidney Int 74: 158–169.
De Broe ME (2012). Chinese herbs nephropathy and Balkan endemic
nephropathy: toward a single entity, aristolochic acid nephropathy.
Kidney Int 81: 513–515.
Devilliers M, Busserolles J, Lolignier S, Deval E, Pereira V, Alloui A
et al. (2013). Activation of TREK-1 by morphine results in analgesia
without adverse side effects. Nat Commun 4: 2941.
Dobler T, Springauf A, Tovornik S, Weber M, Schmitt A, Sedlmeier R
et al. (2007). TRESK two-pore-domain K+ channels constitute a
signiﬁcant component of background potassium currents in murine
dorsal root ganglion neurones. J Physiol 585: 867–879.
Enyedi P , Czirják G (2010). Molecular background of leak K
+
currents:
two-pore domain potassium channels. Physiol Rev 90: 559–605.
Enyedi P , Czirják G (2015). Properties, regulation, pharmacology,
and functions of the K p channel, TRESK. Pﬂugers Arch 467: 945–958.
Feliciangeli S, Chatelain FC, Bichet D, Lesage F (2015). The family of
K2P channels: salient structural and functional properties. J Physiol
593: 2587–2603.
Fink M, Duprat F, Lesage F, Reyes R, Romey G, Heurteaux C et al.
(1996). Cloning, functional expression and brain localization of a
novel unconventional outward rectiﬁer K+ channel. EMBO J 15:
6854–6862.
Grollman AP , Shibutani S, Moriya M, Miller F, Wu L, Moll U et al.
(2007). Aristolochic acid and the etiology of endemic (Balkan)
nephropathy. Proc Natl Acad Sci U S A 104: 12129–12134.
HoangML, Chen C-H, Sidorenko VS, He J, Dickman KG, Yun BH et al.
(2013). Mutational signature of aristolochic acid exposure as revealed
by whole-exome sequencing. Sci Transl Med 5: 197ra102.
IARC (2002). Some traditional herbal medicines, some mycotoxins,
naphthalene and styrene. IARCMonogr Eval Carcinog Risks Hum 82:
1–556.
IARC (2012). Plants containing aristolochic acid. IARC Monogr Eval
Carcinog Risks Hum 100a: 347–361.
Kang D, Mariash E, Kim D (2004). Functional expression of TRESK-2,
a new member of the tandem-pore K+ channel family. J Biol Chem
279: 28063–28070.
Kang D, Kim D (2006). TREK-2 (K2P10.1) and TRESK (K2P18.1) are
major background K+ channels in dorsal root ganglion neurons. Am J
Physiol Cell Physiol 291: C138–C146.
Kim SH, Lee Y , Akitake B, Woodward OM, Guggino WB, Montell C
(2010). Drosophila TRPA1 channel mediates chemical avoidance in
gustatory receptor neurons. Proc Natl Acad Sci U S A 107: 8440–8445.
Kim S, Lee Y , Tak HM, Park HJ, Sohn YS, Hwang S et al. (2013).
Identiﬁcation of blocker binding site in mouse TRESK by molecular
modeling and mutational studies. Biochim Biophys Acta 1828:
1131–1142.
Kumar NN, Velic A, Soliz J, Shi Y , Li K, Wang S et al. (2015).
Regulation of breathing by CO requires the proton-activated
receptor GPR4 in retrotrapezoid nucleus neurons. Science 348:
1255–1260.
Lafrenière RG, Cader MZ, Poulin JF, Andres-Enguix I, Simoneau M,
Gupta N et al. (2010). A dominant-negative mutation in the TRESK
potassium channel is linked to familial migraine with aura. Nat Med
16: 1157–1160.
Regulation of K2P channels by aristolochic acid BJP
British Journal of Pharmacology (2016) •• ••–•• 13
Lennertz RC, Tsunozaki M, Bautista DM, Stucky CL (2010).
Physiological basis of tingling paresthesia evoked by hydroxy-alpha-
sanshool. J Neurosci 30: 4353–4361.
Lopes CM, Franks NP , Lieb WR (1998). Actions of general
anaesthetics and arachidonic pathway inhibitors on K+ currents
activated by volatile anaesthetics and FMRFamide in molluscan
neurones. Br J Pharmacol 125: 309–318.
Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier
F et al. (2013). A novel channelopathy in pulmonary arterial
hypertension. N Engl J Med 369: 351–361.
Marsh B, Acosta C, Djouhri L, Lawson SN (2012). Leak K channel
mRNAs in dorsal root ganglia: relation to inﬂammation and
spontaneous pain behaviour. Mol Cell Neurosci 49: 375–386.
Mathie A (2010). Ion channels as novel therapeutic targets in the
treatment of pain. J Pharm Pharmacol 62: 1089–1095.
Mathie A, Al-Moubarak E, Veale EL (2010). Gating of two pore
domain potassium channels. J Physiol 588: 3149–3156.
Mathie A, Veale EL (2015). Two-pore domain potassium channels:
potential therapeutic targets for the treatment of pain. Pﬂugers Arch
467: 931–943.
Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP ,
Buneman OP et al. (2014). The IUPHAR/BPS guide to
PHARMACOLOGY: an expert-driven knowledge base of drug targets
and their ligands. Nucleic Acids Res 42: D1098–D1106.
Poon SL, Pang S-T, McPherson JR, Yu W, Huang KK, Guan P et al.
(2013). Genome-wide mutational signatures of aristolochic acid and
its application as a screening tool. Sci Transl Med 5: 197ra101.
Reyes R, Duprat F, Lesage F, FinkM, Salinas M, Farman N et al. (1998).
Cloning and expression of a novel pH-sensitive two pore domain K+
channel from human kidney. J Biol Chem 273: 30863–30869.
Roch A, Shlyonsky V, Goolaerts A, Mies F, Sariban-Sohraby S (2006).
Halothane directly modiﬁes Na+ and K+ channel activities in
cultured human alveolar epithelial cells. Mol Pharmacol 69:
1755–1762.
Sano Y , Inamura K, Miyake A, Mochizuki S, Kitada C, Yokoi H et al.
(2003). A novel two-pore domain K+ channel, TRESK, is localized in
the spinal cord. J Biol Chem 278: 27406–27412.
Scarborough J (2011). Ancient medicinal use of Aristolochia:
birthwort’s tradition and toxicity. Pharm Hist 53: 3–21.
Sepúlveda FV, Pablo Cid L, Teulon J, Niemeyer MI (2015). Molecular
aspects of structure, gating, and physiology of pH-sensitive
background K2P and Kir K+-transport channels. Physiol Rev 95:
179–217.
Smith HI (1929). Materia medica of the Bella Coola and neighboring
tribes of British Columbia. Natl Mus Can Bull 56: 47–68.
Soderquist RS, Danilov AV, Eastman A (2014). Gossypol increases
expression of the pro-apoptotic BH3-only protein NOXA through a
novel mechanism involving phospholipase A2, cytoplasmic calcium,
and endoplasmic reticulum stress. J Biol Chem 289: 16190–16199.
Thomas D, Plant LD, Wilkens CM, McCrossan ZA, Goldstein SA
(2008). Alternative translation initiation in rat brain yields K2P2.1
potassium channels permeable to sodium. Neuron 58: 859–870.
Toncheva D, Mihailova-Hristova M, Vazharova R, Staneva R,
Karachanak S, Dimitrov P et al. (2014). NGS nominated CELA1,
HSPG2, and KCNK5 as candidate genes for predisposition to Balkan
endemic nephropathy. Biomed Res Int 2014: 920723. doi: 10.1155/
2014/920723
Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D,
DratwaM, Jadoul M et al. (1993). Rapidly progressive interstitial renal
ﬁbrosis in young women: association with slimming regimen
including Chinese herbs. Lancet 341: 387–391.
Veale EL, Al-Moubarak E, Bajaria N, Omoto K, Cao L, Tucker SJ et al.
(2014a). Inﬂuence of the N terminus on the biophysical properties
and pharmacology of TREK1 potassium channels. Mol Pharmacol 85:
671–681.
Veale EL, Hassan M, Walsh Y , Al-Moubarak E, Mathie A (2014b).
Recovery of current through mutated TASK3 potassium channels
underlying Birk Barel syndrome. Mol Pharmacol 85: 397–407.
Veale EL, Rees KA, Mathie A, Trapp S (2010). Dominant negative
effects of a non-conducting TREK1 splice variant expressed in brain. J
Biol Chem 285: 29295–29304.
Warth R, Barrière H, Meneton P , Bloch M, Thomas J, Tauc M et al.
(2004). Proximal renal tubular acidosis in TASK2 K+ channel-
deﬁcient mice reveals a mechanism for stabilizing bicarbonate
transport. Proc Natl Acad Sci U S A 101: 8215–8220.
Zilberberg N, Ilan N, Goldstein SAN (2001). KCNK0: opening and
closing the 2-P domain potassium leak channel entails “C-type”
gating of the outer pore. Neuron 32: 635–648.
Supporting Information
Additional Supporting Information may be found in the on-
line version of this article at the publisher’s web-site:
http://dx.doi.org/10.1111/bph.13465
Figure S1 Aristolochic acid (AristA) has no effect on the two
pore domain potassium channels, TASK3 and THIK1
BJP
E L Veale and A Mathie
14 British Journal of Pharmacology (2016) •• ••–••
